Serving as the primary IND for TScan’s solid tumour programme, T-Plex will enable customised combinations of T cell receptor (TCR)-engineered T cell therapies (TCR-T) to be given to
The post TScan Therapeutics receives FDA clearance for IND applications appeared first on Pharmaceutical Business review.